Cambridge Healthtech Institute’s 4th Annual

Preclinical and Translational Immuno-Oncology

Predictive Preclinical Models and Translational Strategies for Cancer Immunotherapy

August 6-7, 2019

The recent advancements in immunotherapies, such as immune checkpoint modulators, bispecific antibodies, and adoptive T cell transfer, are shifting the way cancer patients are treated. Rapid development of novel immuno-oncology programs is creating the need for predictive preclinical models and translational strategies to understand combination immunotherapy, study responses and resistance to cancer immunotherapy, and identify novel biomarkers and targets. Please join Cambridge Healthtech Institute’s Fourth Annual Preclinical and Translational Immuno-Oncology conference and learn about new clinically-relevant models for screening IO therapies and translational strategies to support clinical IO programs.  

DEVELOPING CLINICALLY-RELEVANT MOUSE MODELS FOR IMMUNO-ONCOLOGY

Exploring Checkpoint Biology Using Syngeneic Tumor Models
Fiona Sharp, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research

Using Humanized Mouse Models to Evaluate Cell Engagers
Virna Cortez-Retamozo, PhD, Lab Head, Senior Scientist, Oncology-Pharmacology, Sanofi

Immuno-Competent Mouse Models
Olivier Nolan-Stevaux, PhD, Principal Scientist, Oncology-Immunology Research, Amgen

CELLULAR MODELS FOR IMMUNOTHERAPY DEVELOPMENT

3D Model to Mimic the Microenvironment
Litao Zhang, PhD, Vice President, Leads Discovery and Optimization, Bristol-Myers Squibb

Utilizing 3D Human Immune-Tumor Cell Co-Cultures to Study Immune Oncology Therapies
William Hastings, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research

In vitro CD34-Derived Human Dendritic Cells Provide a Physiologically Relevant System to Evaluate the Potency of Protein Therapeutics That Drive Dendritic Cell Differentiation
Christopher Kemball, PhD, Scientist, Biochemical & Cellular Pharmacology, Genentech

Patient-Derived Microtumors for Functional Compound Testing and Therapeutic Response Prediction
Simge G. Yüz, Scientist, NMI Natural and Medical Sciences Institute at the University of Tübingen

Microfluidic Assembly of Hydrogel-Based Immunogenic Tumor Spheroids for Evaluation of Anticancer Therapies and Biomarker Release
Tania Konry, PhD, Assistant Professor, Pharmaceutical Sciences, Northeastern University

UNDERSTANDING RESPONSE AND RESISTANCE TO IMMUNOTHERAPY

Mechanisms of Resistance to Anti-CD19 CAR T Therapy
John Rossi, Director, Translational Medicine, Kite Pharma

Characterization of Immune Checkpoint Response and Resistance via Genetic, Transcriptomic, and Epigenetic Analyses
Genevieve Boland, MD, PhD, Assistant Professor, Surgery; Director, Melanoma Surgery Program, Massachusetts General Hospital

For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com